BIAF (bioAffinity Technologies) ROCE %: -225.74% (As of Mar. 2026)


BIAF bioAffinity Technologies Inc BIAF
44 GF Score
Price $0.76
GF Value $4.27
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioAffinity Technologies ROCE %?

bioAffinity Technologies BIAF -1.48% 44 ROCE % is -225.74% as of Mar. 2026. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. bioAffinity Technologies's annualized ROCE % for the quarter that ended in Mar. 2026 was -225.74%.

bioAffinity Technologies  (NAS:BIAF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

bioAffinity Technologies ROCE % Related Terms

bioAffinity Technologies ROCE % Historical Data

* Premium members only.

The historical data trend for bioAffinity Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioAffinity Technologies ROCE % Chart

bioAffinity Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 0.00 0.00 -92.60 -190.47 -258.57

bioAffinity Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -380.58 -748.96 -355.49 -144.82 -225.74
BIAF
44GF Score
bioAffinity Technologies Inc BIAF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

bioAffinity Technologies ROCE % Calculation

bioAffinity Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-14.821/( ( (6.514 - 3.105) + (10.961 - 2.906) )/ 2 )
=-14.821/( (3.409+8.055)/ 2 )
=-14.821/5.732
=-258.57 %

bioAffinity Technologies's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-14.464/( ( (10.961 - 2.906) + (7.945 - 3.185) )/ 2 )
=-14.464/( ( 8.055 + 4.76 )/ 2 )
=-14.464/6.4075
=-225.74 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -225.74% mean?
bioAffinity Technologies (BIAF) has a ROCE % of -225.74% as of Mar. 2026.
Is bioAffinity Technologies' ROCE % too high?
bioAffinity Technologies' current ROCE % is -225.74%. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' ROCE % compare to NDRA and ISPC?
bioAffinity Technologies' ROCE % of -225.74% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. bioAffinity Technologies's current ROCE % is -225.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current ROCE % is -225.74%. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current ROCE % is -225.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is bioAffinity Technologies (BIAF) Overvalued in 2026?

Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued. The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.27. GuruFocus considers bioAffinity Technologies to be Possible Value Trap.

Key valuation signals for BIAF:

  • ROCE %: -225.74%
  • GF Value™: $4.27 vs. price of $0.76 (82.2% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioAffinity Technologies Business Description

Address 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score

Get the complete analysis for BIAF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price
$4.27
GF Value